DR. MELISSA KAY THOMAS, MD PHD
Osteopathic Medicine in Boston, MA
License number
Massachusetts 161282
Category
Osteopathic Medicine
Type
Endocrinology, Diabetes & Metabolism
Address
Address
112 Eo112 SUITE NEUROENDOCRINE, Boston, MA 02114
Phone
(617) 726-7948
(617) 726-1241 (Fax)
(617) 724-0287
(617) 726-2894 (Fax)
(617) 726-1241 (Fax)
(617) 724-0287
(617) 726-2894 (Fax)
Professional information
Gift Manager At The Paper Store
Position:
Gift Manager at The Paper Store
Location:
Greater Boston Area
Industry:
Retail
Work:
The Paper Store
- Dedham, MA since Aug 2011
-
Gift Manager
Event Network
Jul 2010 - Aug 2011
-
Assistant Store Director
The Disney Store
Oct 2005 - Jul 2010
-
Assistant Store Manager
The Disney Store
Jul 2005 - Oct 2005
-
Lead Castmember
The Disney Store
Jun 2000 - Jun 2005
-
Castmember
Citizens Bank
Jun 2002 - Dec 2004
-
Senior Teller
Medford Savings Bank
Jul 2001 - Jun 2002
-
Teller
Education:
University of Massachusetts at Lowell 1998 - 2002
BA, English
BA, English
Director Integrated Supply Chain - Raytheon
Position:
Integrated Supply Chain at Raytheon
Location:
Greater Boston Area
Industry:
Defense & Space
Work:
Raytheon
since Sep 2005
-
Integrated Supply Chain
Invensys
Jan 1999 - Sep 2005
-
Director Electronics Supply Chain
Education:
Clarkson University 1984 - 1987
B.S., Industrial Engineering
B.S., Industrial Engineering
Account Manager At Netria Corporation
Position:
Account Manager at Netria Corporation
Location:
Greater Boston Area
Industry:
Computer Hardware
Work:
Netria Corporation
-
Account Manager
Owner At Melissa M Thomas Cpa
Position:
owner at Melissa M Thomas CPA
Location:
Greater Boston Area
Industry:
Accounting
Work:
Melissa M Thomas CPA
-
owner
Method Of Pre-Inducing A State Of Immune Tolerance Before Organ Transplantation
US Patent:
6923959, Aug 2, 2005
Filed:
May 2, 2002
Appl. No.:
10/136891
Inventors:
Joel F. Habener - Newton Centre MA, US
Henryk Zulewski - Basel, CH
Elizabeth J. Abraham - Quincy MA, US
Mario Vallejo - Madrid, ES
Denise L. Faustman - Weston MA, US
Melissa K. Thomas - Boston MA, US
Henryk Zulewski - Basel, CH
Elizabeth J. Abraham - Quincy MA, US
Mario Vallejo - Madrid, ES
Denise L. Faustman - Weston MA, US
Melissa K. Thomas - Boston MA, US
Assignee:
The General Hospital Corporation - Boston MA
International Classification:
A61K035/12, C12N005/00
US Classification:
424 937, 424 931, 424520, 435 11, 435 4, 435325
Abstract:
Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin has been identified as a molecular marker for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby nestin-positive stem cells can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed. Methods are described whereby pancreatic stem cells can be isolated, expanded, and transplanted into a patient in need thereof, either allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting cells or other cells.
Stem Cells Of The Islets Of Langerhans And Their Use In Treating Diabetes Mellitus
US Patent:
2003008, May 1, 2003
Filed:
Apr 11, 2002
Appl. No.:
10/120687
Inventors:
Joel Habener - Newton Centre MA, US
Henryk Zulewski - Basel, CH
Melissa Thomas - Boston MA, US
Elizabeth Abraham - Quincy MA, US
Mario Vallejo - Madrid, ES
Colin Leech - Boston MA, US
Anna Nolan - Brookline MA, US
Andreas Lechner - Boston MA, US
Henryk Zulewski - Basel, CH
Melissa Thomas - Boston MA, US
Elizabeth Abraham - Quincy MA, US
Mario Vallejo - Madrid, ES
Colin Leech - Boston MA, US
Anna Nolan - Brookline MA, US
Andreas Lechner - Boston MA, US
International Classification:
A61K048/00, C12N005/08
US Classification:
424/093210, 435/366000
Abstract:
Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin and ABCG2 have been identified as molecular markers for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby nestin and/or ABCG2-positive stem cells can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed. Methods are described whereby pancreatic stem cells can be isolated, expanded, and transplanted into a patient in need thereof, either allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting cells or other cells.
Stem Cells Of The Islets Of Langerhans And Their Use In Treating Diabetes Mellitus
US Patent:
7544510, Jun 9, 2009
Filed:
Apr 24, 2006
Appl. No.:
11/410412
Inventors:
Joel F. Habener - Newton Centre MA, US
Elizabeth J. Abraham - Andover MA, US
Henryk Zulewski - Binningen, CH
Melissa K. Thomas - Boston MA, US
Mario Vallejo - Madrid, ES
Elizabeth J. Abraham - Andover MA, US
Henryk Zulewski - Binningen, CH
Melissa K. Thomas - Boston MA, US
Mario Vallejo - Madrid, ES
Assignee:
The General Hospital Corporation - Boston MA
International Classification:
C12N 5/00, C12N 5/06
US Classification:
435325, 435395, 435402
Abstract:
Methods and compositions are described for the treatment of type I insulin-dependent diabetes mellitus and other conditions using newly identified stem cells that are capable of differentiation into a variety of pancreatic islet cells, including insulin-producing beta cells, as well as hepatocytes. Nestin has been identified as a molecular marker for pancreatic stem cells, while cytokeratin-19 serves as a marker for a distinct class of islet ductal cells. Methods are described whereby nestin-positive stem cells can be isolated from pancreatic islets and cultured to obtain further stem cells or pseudo-islet like structures. Methods for ex vivo differentiation of the pancreatic stem cells are disclosed. Methods are described whereby pancreatic stem cells can be isolated, expanded, and transplanted into a patient in need thereof, either allogeneically, isogeneically or xenogenically, to provide replacement for lost or damaged insulin-secreting cells or other cells.
Cyclic Gmp-Binding, Cyclic Gmp-Specific Phosphodiesterase Materials And Methods
US Patent:
2003005, Mar 20, 2003
Filed:
Apr 3, 2002
Appl. No.:
10/115515
Inventors:
Joseph Beavo - Seattle WA, US
Jackie Corbin - Nashville TN, US
Kenneth Ferguson - Bothell WA, US
Sharron Francis - Nashville TN, US
Ann Kadlecek - Seattle WA, US
Kate Loughney - Seattle WA, US
William Sonnenburg - Mountlake Terrace WA, US
Melissa Thomas - Boston MA, US
Jackie Corbin - Nashville TN, US
Kenneth Ferguson - Bothell WA, US
Sharron Francis - Nashville TN, US
Ann Kadlecek - Seattle WA, US
Kate Loughney - Seattle WA, US
William Sonnenburg - Mountlake Terrace WA, US
Melissa Thomas - Boston MA, US
Assignee:
ICOS Corporation
International Classification:
A61K038/17, C07H021/04, C12N009/20, C12P021/02, C12N005/06
US Classification:
514/012000, 435/198000, 435/069100, 435/325000, 435/320100, 536/023200
Abstract:
The present invention provides novel purified and isolated nucleotide sequences encoding the cGMP-binding, cGMP-specific phosphodiesterase designated cGB-PDE. Also provided by the invention are methods and materials for the recombinant production of cGB-PDE polypeptide products and methods for identifying compounds which modulate the enzymatic activity of cGB-PDE polypeptides.
Methods To Stimulate Insulin Production By Pancreatic Beta-Cells
US Patent:
6903073, Jun 7, 2005
Filed:
Dec 8, 2000
Appl. No.:
09/733634
Inventors:
Joel F. Habener - Newton Centre MA, US
Melissa K. Thomas - Boston MA, US
Melissa K. Thomas - Boston MA, US
Assignee:
The General Hospital Corporation - Boston MA
International Classification:
A61K038/00
US Classification:
514 12, 514 2, 530300, 530325
Abstract:
The invention features a method of treating deficiency of insulin in a patient, comprising administering to a patient in need thereof hedgehog protein or nucleic acid in an amount effective to raise the level of insulin in the patient.
Cyclic Gmp-Binding, Cyclic Gmp-Specific Phosphodiesterase Materials And Methods
US Patent:
2005019, Sep 8, 2005
Filed:
Jan 28, 2003
Appl. No.:
10/353575
Inventors:
Joseph Beavo - Seattle WA, US
Jackie Corbin - Nashville TN, US
Kenneth Ferguson - Bothell WA, US
Sharron Francis - Nashville TN, US
Ann Kadlecek - Madison CT, US
Kate Loughney - Seattle WA, US
William Sonnenburg - Spring TX, US
Melissa Thomas - Boston MA, US
Jackie Corbin - Nashville TN, US
Kenneth Ferguson - Bothell WA, US
Sharron Francis - Nashville TN, US
Ann Kadlecek - Madison CT, US
Kate Loughney - Seattle WA, US
William Sonnenburg - Spring TX, US
Melissa Thomas - Boston MA, US
International Classification:
C12N009/16, C07H021/04, A61K031/519
US Classification:
435069100, 435196000, 435320100, 435325000, 514252160, 536023200
Abstract:
The present invention provides novel purified and isolated nucleotide sequences encoding the cGMP-binding. cGMP-specific phosphodiesterase designated cGB-PDE. Also provided by the invention are methods and materials for the recombinant production of cGB-PDE polypeptide products and methods for identifying compounds which modulate the enzymatic activity of cGB-PDE polypeptides.